The Association of G9a Protein and the Outcome of Patients With Cervical Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
G9a protein was approved to be highly associated with recurrence of breast cancer, gastric cancer, hepatocellular cancer, prostate cancer and lung cancer. Therefore, the aim of this study was to clarify the association and G9a protein and cervical cancer by analyzing the immunohistochemical staining of G9a protein to the histopathologic specimen of cervical cancer and clinical data.
determine whether G9a protein is a risk factor of overall survival of patients with cervical cancer [ Time Frame: From the date of primary treatment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months ]
Secondary Outcome Measures
determine whether G9a protein is a risk factor of progression-free survival of patients with cervical cancer [ Time Frame: From the date of primary treatment until the date of first documented progression or last follow-up, whichever came first, assessed up to 100 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 99 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with cervical cancer, and underwent primary treatment (surgery, radiotherapy or chemotherapy) in Far Eastern Memorial Hospital